Advanced Renal Cell Carcinoma: Incorporating Quality of Life into Treatment Sequencing
Dr. Monty Pal discusses the importance of prioritizing quality of life and treatment tolerability when sequencing therapies for advanced renal cell carcinoma. He emphasizes that treatment plans should be individualized based on a patient's specific clinical status and previous reactions to tyrosine kinase inhibitors.
Why it matters
This approach shifts the focus of cancer care from purely disease control to patient-centered outcomes, which is critical for long-term management of chronic advanced cancers.
Dr. Monty Pal discusses the growing importance of quality of life and long-term tolerability when selecting subsequent therapies for advanced renal cell carcinoma (RCC). He explains that although maintaining disease control remains an important objective, treatment priorities often evolve in later lines of therapy to place greater emphasis on symptom management, preservation of daily functioning, and minimizing treatment-related toxicity. Dr.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in